Our research group focuses on utilizing modified oligonucleotides and drugs to develop advanced nanostructures for therapeutic and diagnostic purposes. By harnessing the inherent properties of nanoparticles such as albumin, gold, and iron oxide, we aim to address the challenges associated with pancreatic cancer, uveal melanoma, COVID-19, and Duchenne muscular dystrophy. Our team designs oligonucleotides to mimic or inhibit various nucleic acids, including mRNA, miRNAs, and lncRNAs. These oligonucleotides are then conjugated to nanoparticles using cleavage linkers, enabling targeted delivery and controlled release. Our approaches offer promising prospects in the development of precise and effective therapeutics and diagnostics.